Kaiyu Qian

Researcher, Zhongnan Hospital of Wuhan University
  • China

USP43 promotes gemcitabine resistance in bladder cancer by stabilizing E2F1 to regulate cholesterol homeostasis

Gemcitabine (GEM) resistance remains a critical barrier in the treatment of bladder cancer (BLCA). Based on the observation that metabolic reprogramming drives chemoresistance, we identified USP43 as a promoter of GEM resistance via an E2F1-driven mechanism that modulates cholesterol metabolism.
Go to the profile of Lingao Ju +4
Lingao Ju and 4 others
Jan 07, 2026

Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin β1 localization

Activating the mevalonate (MVA) pathway increases bladder cancer (BLCA) spread. High MVA enzyme levels predict worse outcomes. Drugs like zoledronic acid or simvastatin blocking this pathway reduce cancer cell migration by affecting the protein RhoB. Targeting the MVA pathway could help treat BLCA.
Go to the profile of Gang  Wang +3
Gang Wang and 3 others
Nov 09, 2024

Pedigree analysis of a POLD1 germline mutation in urothelial carcinoma shows a close association between different mutation burdens and overall survival

We found a bladder cancer family in which germline mutations of POLD1 and somatic mutations of FGFR3 were prevalent. We studied the changes in the immune microenvironment in patients with this mutation in our cohort and a TCGA cohort and predicted the prognosis of patients with this subtype.
Go to the profile of Yu Xiao +3
Yu Xiao and 3 others
Oct 10, 2024